Gilead's Strong HIV Quarter Plus Bictegravir May Portend Sector Dominance
Sales of Gilead's TAF-based regimens for HIV continue to grow and should be augmented by elvitegravir successor bictegravir. The company's future growth is unclear, however, without M&A.
You may also be interested in...
The Japanese pharmaceutical companies will work with the Global Antibiotic Research and Development Partnership on screening targets for utility against WHO-listed priority pathogens. Avacta and LG Chem collaborate around the former’s Affimer technology.
Gilead thinks 2017 HCV sales could reach as high as $9bn, still down from 2016, but higher than projected six months ago. Meanwhile, sales of TAF-based HIV regimens continue to grow and gain market share.
Part two of Scrip's preview of first quarter earnings: product launches, management priorities, pricing strategies and biosimilar competition are key themes at the half-year mark.